Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia.

  title={Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia.},
  author={Constantinos Chrysostomou and Victor O. Morell and Peter A Wearden and Joan S{\'a}nchez-de-Toledo and Edmund H. Jooste and Lee Beerman},
  journal={Congenital heart disease},
  volume={8 1},
OBJECTIVES The current drug of choice for reentrant supraventricular tachycardia (SVT) is adenosine followed by verapamil or diltiazem. Although limitations and significant adverse events have been encountered over the years, an alternative effective and safe agent has not been available. Dexmedetomidine has recently been shown to have potential antiarrhythmic effects, and here we describe our experience in the acute termination of reentrant SVT. DESIGN Retrospective case series. SETTING… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 13 extracted citations


Publications referenced by this paper.
Showing 1-10 of 23 references

Pediatric Basic and Advanced Life Support Chapter Collaborators. Part 10: pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency

  • ME Kleinman, AR de Caen, L Chameides
  • 2010

Similar Papers

Loading similar papers…